144290-77-7Relevant academic research and scientific papers
Diphenyl 2-pyridylphosphine and di-tert-butyl azodicarboxylate:convenient reagents for the Mitsunobu reaction
Kiankarimi, Mehrak,Lowe, Richard,McCarthy, James R.,Whitten, Jeffrey P.
, p. 4497 - 4500 (1999)
New reagents that resolve the problem of separating products from the numerous byproducts in the Mitsunobu reaction have been introduced. Substitution of a basic triarylphosphine and an acid labile azodicarboxylate for triphenylphosphine and diethy azodic
Cyclohexyl-substituted non-fullerene small-molecule acceptors for organic solar cells
Hong, Seunggyun,Song, Chang Eun,Ryu, Du Hyeon,Lee, Sang Kyu,Shin, Won Suk,Lim, Eunhee
, p. 10373 - 10382 (2021)
In this paper, two cyclohexyl-substituted non-fullerene small molecules, T2-Cy6MRH and T2-Cy6PRH, are designed to have the same molecular backbone of a bithiophene (T2) core and rhodanine (RH) end groups. T2-Cy6MRH and T2-Cy6PRH can be synthesized via two
Nickel/Cobalt-Catalyzed C(sp3)-C(sp3) Cross-Coupling of Alkyl Halides with Alkyl Tosylates
Komeyama, Kimihiro,Michiyuki, Takuya,Osaka, Itaru
, p. 9285 - 9291 (2019/10/11)
The C(sp3)-C(sp3) cross-coupling of alkyl halides with alkyl tosylates has been developed by employing a combination of nickel and nucleophilic cobalt catalysts in the presence of a manganese reductant. This method provides a straightforward route to a diverse set of not only secondary-primary but also primary-primary C(sp3)-C(sp3) linkages under mild conditions without using alkyl-metallic reagents. Mechanistic studies suggest the formation of alkyl radicals from both alkyl halides and alkyl tosylates. Additionally, cross-coupling could be applied to the short-step synthesis of a histone deacetylase inhibitor, Vorinostat.
Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure
Manickam, Manoj,Jalani, Hitesh B.,Pillaiyar, Thanigaimalai,Sharma, Niti,Boggu, Pulla Reddy,Venkateswararao, Eeda,Lee, You-Jung,Jeon, Eun-Seok,Jung, Sang-Hun
, p. 379 - 391 (2017/04/24)
A series of flexible urea derivatives have been synthesized and demonstrated as selective cardiac myosin ATPase activator. Among them 1-phenethyl-3-(3-phenylpropyl)urea (1, cardiac myosin ATPase activation at 10?μM?=?51.1%; FS?=?18.90; EF?=?12.15) and 1-benzyl-3-(3-phenylpropyl)urea (9, cardiac myosin ATPase activation?=?53.3%; FS?=?30.04; EF?=?18.27) showed significant activity in?vitro and in?vivo. The change of phenyl ring with tetrahydropyran-4-yl moiety viz., 1-(3-phenylpropyl)-3-((tetrahydro-2H-pyran-4-yl)methyl)urea (14, cardiac myosin ATPase activation?=?81.4%; FS?=?20.50; EF?=?13.10), and morpholine moiety viz., 1-(2-morpholinoethyl)-3-(3-phenylpropyl)urea (21, cardiac myosin ATPase activation?=?44.0%; FS?=?24.79; EF?=?15.65), proved to be efficient to activate the cardiac myosin. The potent compounds 1, 9, 14 and 21 were found to be selective for cardiac myosin over skeletal and smooth myosins. Thus, these urea derivatives are potent scaffold to develop as a newer cardiac myosin activator for the treatment of systolic heart failure.
Compounds with cardiac myosin activating function and pharmaceutical composition containing the same for treating or preventing heart failure
-
, (2017/02/02)
The present invention relates to a compound having a cardiotonic activating function and a pharmaceutical composition containing the same. The composition comprising the compound according to the present invention is effective in preventing or treating heart failure. In addition, the compound is represented by chemical formula 2 or is pharmaceutically acceptable salt thereof.COPYRIGHT KIPO 2016
Compounds with cardiac myosin activating function and pharmaceutical composition containing the same for treating or preventing heart failure
-
, (2016/10/07)
Disclosed are a compound having cardiotonic activity and a pharmaceutical composition containing the same, and the composition containing the compound, according to the present invention, is useful for preventing and treating heart failure.COPYRIGHT KIPO 2016
N-Alkenyl and cycloalkyl carbamates as dual acting histamine H3 and H4 receptor ligands
Wicek, Ma?gorzata,Kottke, Tim,Ligneau, Xavier,Schunack, Walter,Seifert, Roland,Stark, Holger,Handzlik, Jadwiga,Kie?-Kononowicz, Katarzyna
experimental part, p. 2850 - 2858 (2011/06/21)
Previous studies have shown that several imidazole derivatives posses affinity to histamine H3 and H4 receptors. Continuing our study on structural requirements responsible for affinity and selectivity for H3/H4 receptor subtypes, two series of 3-(1H-imidazol-4-yl)propyl carbamates were prepared: a series of unsaturated alkyl derivatives (1-9) and a series possessing a cycloalkyl group different distances to the carbamate moiety (10-13). The compounds were tested for their affinities at the human histamine H3 receptor, stably expressed in CHO-K1 cells. Compounds 1, 2, 5-7, 10-13 were investigated for their affinities at the human histamine H4 receptor co-expressed with Gαi2 and Gβ1γ2 subunits in Sf9 cells. To expand the pharmacological profile, compounds were further tested for their H3 receptor antagonist activity on guinea pig ileum and in vivo after oral administration to mice. All tested compounds exhibited good affinity for the human histamine H3 receptor with Ki values in the range from 14 to 194 nM. All compounds were active in vivo after peroral administration (p.o.) to Swiss mice, thus demonstrating their ability to cross the blood-brain barrier. The most potent H3 receptor ligand of these series was compound 5, 3-(1H-imidazol-4-yl)propyl pent-4-enylcarbamate with the highest affinity (Ki = 14 nM). Additionally, compound 3 showed remarkable central nervous system (CNS) H3R activity, increasing the Nτ-methylhistamine levels in mice with an ED 50 value of 0.55 mg/kg, p.o. evidencing therefore, a twofold increase of inverse agonist/antagonist potency compared to the reference inverse agonist/antagonist thioperamide. In this study, the imidazole propyloxy carbamate moiety was kept constant. The different lipophilic moieties connected to the carbamate functionality in the eastern part of the molecule had a range of influences on the human H4 receptor affinity (154-1326 nM).
Synthesis and histamine H2 agonistic activity of arpromidine analogues: replacement of the pheniramine-like moiety by non-heterocyclic groups
Buschauer, A,Friese-Kimmel A,Baumann, G,Schunack, W
, p. 321 - 330 (2007/10/02)
Analogues of the potent histamine H2 agonist arpromidine, characterized by non-hetrocyclic groups (phenyl, cyclohexyl, alkyl) instead of the pheniramine-like portion, were prepared and tested for their H2 agonistic and H1 antagonistic activity in the isolated guiea pig right atrium and ileum, respectively.In the diphenylpropylguanidine series an increase in H2 agonistic potency resulted from mono- or difluorination at one or both phenyl rings in the meta and/or para position (pD2 7.75 vs pD2 = 7.15 for the unsubstituted parent compound).Compounds chlorinated atboth phenyl rings were considerably less potent.Highest combined H2 agonistic/H1 antagonistic potency was found in the 4-fluorophenyl series.The arpromidine analogue with cyclohexyl and methyl group instead of phenyl and pyridine ring proved to be 30 times more potent than histamine in the atrium.The H1 antagonistic potency in cyclohexyl compounds was lower than in the diaryl series.Thus, aromatic rings appear not to be required for high H2 agonistic potency but are useful for combined H2 agonistic/H1 antagonistic activity. histamine / H2 receptor / H2 agonist / arpromidine / impromidine / H1 antagonist / antihistamine
